百普賽斯(301080.SZ):預計2024年淨利潤同比下降8.85%-21.87%
格隆匯1月16日丨百普賽斯(301080.SZ)公佈,預計2024年營業收入64,500.00萬元-66,000.00萬元,比上年同期增長18.64%-21.40%,淨利潤12,000.00萬元-14,000.00萬元,比上年同期下降8.85%-21.87%,扣非淨利潤11,000.00萬元-13,000.00萬元,比上年同期下降7.41%-21.65%。
公司採用精準服務於生物藥、細胞免疫治療行業研發及生產的市場策略,集中研發及技術優勢推出更符合客户應用的產品。2024年度,公司5,700餘種產品成功實現銷售及應用,涵蓋重組蛋白、抗體、試劑盒等多種產品,產品和服務廣泛應用於腫瘤、自身免疫疾病、心血管病、傳染病等疾病的研發及生產環節,包括藥物篩選及優化、診斷試劑開發及優化、臨牀前實驗及臨牀試驗、藥物生產過程及工藝控制(CMC)等。同時,公司還積極擁抱前沿技術與新模式的結合,例如將重組蛋白試劑與基因剪輯技術、自動化技術、AI技術等相結合,為生物試劑研發領域注入了新的活力,推動了行業的創新與發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.